Delphinidin induces cytotoxicity and potentiates cytoidal effect in combination with arsenite in an acute promyelocytic leukemia NB4 cell line

BO YUAN1,3, SAKI OKUSUMI1, YUTA YOSHINO1, CHIHIRO MORIYAMA1, SACHIKO TANAKA2, TOSHIHIKO HIRANO2, NORIO TAKAGI3 and HIROO TOYODA1

Departments of 1Clinical Molecular Genetics, 2Clinical Pharmacology, and 3Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan

Received February 25, 2015; Accepted April 2, 2015

DOI: 10.3892/or.2015.3963

Abstract. The effects of delphinidin were investigated by focusing on growth inhibition, cell cycle arrest and apoptosis induction in the human acute promyelocytic leukemia (APL) NB4 cell line. Delphinidin exhibited a dose- and time-dependent cytotoxic effect against NB4 cells. Almost no cell cycle arrest, but an apparent increase in the percentage of sub-G1 cells was observed in delphinidin-treated cells. The activation of caspase-8 and -9 was observed as early as 1-h post-exposure to delphinidin, followed by the activation of caspase-3 from 3-h post-exposure. A substantial decrease in the expression level of Bid was also observed as early as 1-h post-exposure. A modest decrease in the mitochondrial membrane potential (ΔΨm) was observed at 3-h post-exposure, followed by a substantial time-dependent decrease in ΔΨm in treated cells. Delphinidin exerted more potent cytotoxicity against NB4 cells than normal peripheral blood mononuclear cells (PBMNCs). In addition, delphinidin in combination with an arsenic derivative arsenite (AsIII), which has demonstrated marked efficacy in patients with APL, achieved an enhanced cytoidal effect against NB4 cells, but lesser on PBMNCs. Treatment of NB4 cells with AsIII plus delphinidin did not increase, but decreased slightly, intracellular arsenic accumulation (As[i]) as compared to that treated with AsIII alone. These results suggested that delphinidin selectively sensitized NB4 cells to AsIII, resulting in the enhancement of AsIII cytotoxicity by strengthening intrinsic/extrinsic pathway-mediated apoptosis induction, rather than affecting the As[i] levels. These observations may offer a rationale for the use of delphinidin to improve the clinical efficacy of AsIII.

Introduction

Acute promyelocytic leukemia (APL) is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, resulting in the fusion of promyelocytic leukemia (PML) and retinoic acid receptor α (RARα) (1-3). Administration of arsenic trioxide (arsenite, AsIII), an arsenic derivative, has demonstrated marked therapeutic efficacy in the treatment of relapsed and refractory APL patients. In order to understand the mode of action of AsIII and provide an effective treatment protocol for individual APL patients, studies have been conducted on the pharmacokinetics of AsIII in APL patients using biological samples such as urine, blood and cerebrospinal fluid (4-7). In this regard, we have clarified the distribution of arsenic metabolites in, not only peripheral blood and cerebrospinal fluid, but also bone marrow from APL patients who had received the consecutive administration of AsIII (5,7,8). The findings on the pharmacokinetics of AsIII in APL patients provide novel insight into the clinical applications of AsIII, and may contribute to improved therapeutic protocols (9).

Although the clinical efficacy of AsIII-based regimens against APL has been reported (6,10), side-effects of AsIII remain a serious concern and limit its clinical applications. Application of new AsIII-based therapies may require the generation of sensitizing strategies for improving the efficacy of AsIII as well as minimizing its side-effects. In this regard, there is emerging interest in the chemotherapeutic application of natural substances, such as tea polyphenols and resveratrol, for cancer treatment (11). Specifically, flavonoids such as quercetin and genistein have been reported to potentiate the apoptotic action of AsIII in leukemic cell lines, such as HL-60, U937 and THP-1 (12,13).

Delphinidin (Fig. 1), a major anthocyanidin known to be present in pigmented fruits and vegetables such as pomegranates, berries, dark grapes, eggplants and red onions, is a diphenylpropane-based polyphenolic ring structure that carries a positive charge in its central ring (14). Delphinidin has gained considerable attention as it appears to possess strong antioxidant/oxidant properties as well as other potentially beneficial characteristics, such as anti-inflammatory, antimutagenic, antiangiogenic, and anti-adipocyte differen-
tiation activities (15-20). Treatment with delphinidin resulted in a reduction of cells in G0 phase and an accumulation in G2/M phase in human HeLa uterine carcinoma cell line, and human CaCo-2 colorectal carcinoma cell line, accompanied by apoptosis induction (18). Yun et al (17) also demonstrated that delphinidin suppresses the NF-κB pathway, resulting in G2/M phase arrest and apoptosis induction in human HCT116 colon cancer cell line and human PC3 prostate cancer cell line (15). Despite investigations into the antitumor activity of delphinidin against various types of cancer cells derived from solid tumors (15-19,21,22), to the best of our knowledge, few studies have been conducted to investigate the effects of delphinidin on leukemic cells (23,24). Although delphinidin and its glycosides have been shown to trigger apoptosis in non-APL HL-60 (PML-RARα negative) cells through a ROS/JNK-mediated mitochondrial death pathway (23,25), the effects of delphinidin on the human APL cell line harboring PML-RARα remain largely unclear.

In the present study, the effects of delphinidin were investigated by focusing on growth inhibition, cell-cycle arrest and apoptosis induction in the APL NB4 cell line (PML-RARα positive). Furthermore, the cytotoxic effects of delphinidin in combination with AsIII were assessed to explore a potential application of delphinidin as an effective chemopreventive and/or chemotherapeutic agent for AsIII-based therapy in patients with hematologic malignancies.

**Materials and methods**

**Materials.** Sodium arsenite (AsIII) was purchased from Tri Chemical Laboratories (Yamanashi, Japan). Delphinidin, RPMI-1640 medium, propidium iodide (PI), ribonuclease A (RNase A) and 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) and phenazine methosulfate (PMS) were obtained from Nichirei Biosciences (Tokyo, Japan) and Wako Pure Chemical Industries (Osaka, Japan), respectively.

**Cell lines and culture conditions.** NB4, a human APL cell line with t(15;17), was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany). Peripheral blood mononuclear cells (PBMCNs) were isolated from three healthy volunteers using Histopaque-1077 (Sigma-Aldrich) according to the method previously described (26). Briefly, 3 ml of heparinized blood was mixed with 5 ml of phosphate-buffered saline (PBS), and loaded on 3 ml of Histopaque-1077. After centrifugation at 400 x g for 30 min at room temperature, the opaque interface containing PBMCNs was transferred to a clean centrifuge tube and washed three times with PBS. The two types of cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS and 100 U/ml of penicillin and 100 µg/ml of streptomycin (Wako Pure Chemical Industries) at 37°C in a humidified atmosphere at 5% CO2 in air. For experiments, the cell density of NB4 and PBMCNs was adjusted to 1x105 ml and 5x103 cells/ml, respectively, prior to the treatments. The present study was approved by the IRB Committee of Tokyo University of Pharmacy and Life Sciences. Informed consent was obtained from all the healthy volunteers.

**XTT assay.** Cell viability was determined by an XTT dye-reduction assay according to the method previously described (27). Briefly, after treatment with various concentrations of delphinidin and AsIII, alone or in combination, for a designated time, the cells were washed with PBS twice and resuspended in an appropriate volume of PBS. An aliquot (0.2 ml) of cell suspension was inoculated into 96-well plates (Iwaki, Tokyo, Japan) followed by the addition of 50 µl XTT/PMS mixed solution (1.5 mM XTT and 0.025 mM PMS). After incubation at 37°C for 4 h, the plates were mixed on a mechanical plate shaker, and absorbance at 450 nm was measured using a microplate reader (Safire; Tecan, Männedorf, Switzerland). The relative cell viability was expressed as the ratio of the absorbance of each treatment group against that of the corresponding untreated control group. The IC50 value of delphinidin was calculated from the cell proliferation inhibition curve. Data are shown as means ± SD from three independent experiments.

**Cell cycle analysis.** After treatment with the IC50 value of delphinidin at 14.0 µM for 24 h, a cell cycle analysis was performed using a FACScanto flow cytometer (Becton-Dickinson, San Jose, CA, USA) according to a method previously described, with modifications (26). To stain cellular DNA, the cells were washed twice with PBS, fixed with 1% paraformaldehyde/PBS for 30 min, washed twice again with PBS, permeabilized in 70% (v/v) cold ethanol and kept at -20°C for at least 4 h. The cell pellets were washed twice with PBS after centrifugation and incubated with 0.25% Triton-X 100 for 5 min on ice. After washing with PBS, the cells were centrifuged and resuspended in 500 µl of PI/RNase A/PBS (5 µg/ml PI and 0.1% RNase A in PBS) and incubated for 30 min in the dark at room temperature. A total of 10,000 events were obtained and Diva software (Becton-Dickinson) and ModFit LT™ ver.3.0 (Verity Software House, Inc., Topsham, ME, USA) were used to calculate the number of cells at each sub-G1, G0/G1, S and G2/M phase fraction.

**Annexin V/PI analysis.** The TACS™ Annexin V-FITC apoptosis detection kit (Trevigen, Gaithersburg, MD, USA) was used for the detection of early apoptotic and late apoptotic/necrotic cells according to the method previously described (26). Briefly, after treatment with 14 µM of delphinidin for 12, 24 and 48 h, respectively, the cells were washed twice with PBS. Cells (1x107) were then resuspended in 100 µl Annexin V incubation reagent (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 µg/ml PI, and...
Annexin V-FITC). The cells were incubated in the dark for 15 min at room temperature, followed by the addition of 400 µl binding buffer. Fluorescence intensities of FITC and PI were measured by a FACSCanto flow cytometer (Becton-Dickinson). A total of 30,000 events were obtained and data were analyzed by Diva software. Annexin V(-)PI(-), annexin V(+)PI(-), and Annexin V(+)PI(+) cells were defined as viable, early apoptotic, and late apoptotic/necrotic cells, respectively.

**Western blot analysis.** Western blot analysis was carried out according to the methods previously described (28). Briefly, after separation of the proteins on an SDS polyacrylamide gel electrophoresis, followed by transferring to a nitrocellulose membrane, the protein bands were detected using the following primary antibodies and dilution ratios: rabbit anti-human caspase-3 (Enzo Life Sciences, New York, NY, USA) at 1:1,000; rabbit anti-human caspase-8 (BD Biosciences, Franklin Lakes, NJ, USA) at 1:4,000; rabbit anti-human caspase-9 (Cell Signaling Technology, Danvers, MA, USA) at 1:1,000; mouse anti-human Bid (BD Biosciences) at 1:1,000; and mouse anti-human β-actin (Sigma) at 1:5,000. Blotted protein bands were detected with respective horseradish peroxidase-conjugated secondary antibodies and an enhanced chemiluminescence (ECL) western blot analysis system (GE Healthcare, Buckinghamshire, UK).

**Measurement of caspase-3, -8 and -9 activities.** Activity of caspase-3, -8 or -9 was measured using the caspase fluorometric assay kit (BioVision, Inc., Milpitas, CA, USA) according to the methods previously described (29). Protein (50 µg/50 µl) was plated on a 96-well plate, followed by the addition of 50 µl of 2x reaction buffer containing 10 mM DTT to each sample, and then 5 µl of 1 mM caspase substrate (final concentration of 50 µM). After incubation at 37˚C for 1 h, fluorescent intensity was measured with a 400 nm excitation filter and 505 nm emission filter using a microplate reader (Safire).

**Determination of loss of mitochondrial membrane potential (ΔΨm).** ΔΨm was determined by flow cytometry after cell loading with Rhodamine 123 as previously described with modifications (26). After treatment with 14 µM of delphinidin for 3, 6, 12 and 24 h, respectively, the cells were washed with PBS, followed by incubation with 10 µM Rhodamine 123 in PBS for 15 min in the dark at room temperature. The fluorescence intensities of Rhodamine 123 were measured by a FACSCanto flow cytometer (Becton-Dickinson). A total of 30,000 events were obtained and data were analyzed by Diva software.

**Analysis of intracellular arsenic accumulation (As[i]).** After exposure of NB4 cells to 2 µM AsIII alone or in combination with 8 µM delphinidin for 0, 1, 3 or 6 h, the cells were washed three times with PBS and harvested in 2% SDS solution. Protein concentrations were determined by Bradford's method using the protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions, and using BSA as the standard. The As[i] was normalized by the amount of proteins and given as parts per billion (ppb) of arsenic per mg of proteins. The analysis of total arsenic was performed by inductively coupled plasma-mass spectrometry (ICP-MS) (Perkin-Elmer Sciex, Thornhill, ON, Canada) according to the methods previously reported (7,27,30).

**Statistical analysis.** Experiments were independently repeated three times, and the results were shown as the mean ± standard deviation (SD) of three assays. The Student’s t-test was used to compare sample means from two groups, and one-way ANOVA followed by the Tukey’s post test was used to compare sample means from more than three groups. P<0.05 was considered to indicate a significant result.

**Results**

**Cytotoxic effect of delphinidin against NB4 cells.** Delphinidin exhibited dose- and time-dependent cytotoxic effects on NB4 cells after treatment with various concentrations of delphinidin (0.3, 1, 3, 10, 20 and 30 µM) for 24 and 48 h (Fig. 2A). When the concentration of delphinidin was increased to 10 µM, statistically significant differences were observed between the delphinidin-exposed and control groups (Fig. 2A). Furthermore, the IC50 values were 14.0 and 8.1 µM for 24- and 48-h treatment, respectively, calculated from the respective cell proliferation inhibition curve. On the other hand, after treatment with various concentrations of delphinidin (3, 10, 30 and 100 µM) for 48 h, the apparent cytotoxicity of delphinidin was observed in the PBMNCs.
only when the concentration was >10 µM, and the IC_{50} value of delphinidin was 39.7 µM (Fig. 2B). These results showed that delphinidin exerted more potent cytotoxicity against NB4 cells than normal PBMCs. Therefore, subsequent experiments were conducted to clarify the details underlying delphinidin-induced cytotoxicity in NB4 cells following
treatment with the IC₅₀ value of delphinidin at 14.0 µM for the indicated time-point.

**Effect of delphinidin on the cell cycle profiling of NB4 cells.** The flow cytometric analysis showed that almost no cell arrest was observed in NB4 cells, although there was a decrease in the number of cells in S and G₂/M phases following treatment with 14.0 µM delphinidin for 24 h (Fig. 3). An apparent increase in the number of cells in sub-G₁ phase was observed, indicating apoptosis induction in NB4 cells treated with delphinidin (Fig. 3A).

**Apoptosis induction in NB4 cells treated with delphinidin.** After treatment with 14.0 µM of delphinidin for 12, 24 and 48 h, apoptosis was measured with FACS analysis. Consistent with cell-cycle results (Fig. 3A), the cells treated with 14.0 µM delphinidin underwent early and late stage apoptosis in a time-dependent manner as compared with the control group, as demonstrated by the transition from Annexin V(-)PI(-) to Annexin V(+)PI(-), and then to Annexin V(+)PI(+) (Fig. 4). The transition of cells through these three stages clearly indicated the induction of apoptosis in NB4 cells treated with delphinidin.

**Delphinidin-mediated caspase activation and Bid truncation in NB4 cells.** After treatment of NB4 cells with 14.0 µM of delphinidin for 1, 3, 6, 12 and 24 h, western blot analysis was conducted to determine the activation of caspase-3, -8, and -9, as well as Bid truncation. As shown in Fig. 5A, the cleaved forms of caspase-8 and -9 were observed as early as 1-h post-exposure to delphinidin and continued up to 24 h, indicating the activation of caspase-8 and -9 in the cells. Activation of caspase-3 was also confirmed based on the appearance of its cleaved form from 3-h post-exposure and continued up to 24 h (Fig. 5A). Furthermore, an approximate 2- and 3- to 4-fold increase in the activity of caspase-3, -8, and -9, respectively, was observed in NB4 cells after treatment for 24 and 48 h, respectively (Fig. 5B). Moreover, it was confirmed that no alteration in caspase activation was observed in the control group cells between 24- and 48-h treatment. Similar to the activation pattern of caspase-8 and -9, a substantial decrease in the expression level of Bid was observed as early as 1-h post-exposure, indicating its truncation in NB4 cells treated with delphinidin (Fig. 5A).

**Delphinidin-induced loss of mitochondrial membrane potential (ΔΨm) in NB4 cells.** After treatment with 14.0 µM of delphinidin for 3, 6, 12 and 24 h, Rhodamine 123, a cell-permeant cationic fluorescent dye, was used to assay ΔΨm in NB4 cells. As shown in Fig. 6, only a modest decrease in ΔΨm was observed at 3 h post-exposure, followed by a substantial time-dependent decrease in ΔΨm in NB4 cells treated with delphinidin.

**Enhanced cytotoxic effect of delphinidin in combination with As[iii] in NB4 cells.** Since delphinidin exerted more potent cytotoxicity against NB4 cells than normal PBMNCs (Fig. 2), we examined the potential for the application of the combination of delphinidin and As[iii], which has demonstrated notable clinical efficacy in the treatment of relapsed and refractory APL patients (9,31). To clarify whether enhanced cytotoxicity was induced by the combination treatment, 8 µM of delphinidin, which was estimated to inhibit ~20% of cell proliferation in NB4 cells by the cell proliferation inhibition curve for 24 h, was combined with As[iii]. After treatment with delphinidin (8 µM) and As[iii] [2 µM, concentrations achieved clinically (9), alone or in combination, respectively, for 24 h, cell viability was determined by XTT assay. As shown in Fig. 7A, cell viability significantly decreased to 77.5, 83.3 and 31.9% of the control when treated with delphinidin and As[iii] either alone or in combination, respectively. In agreement with the results in Fig. 2B, 8 µM of delphinidin did not exhibit cytotoxicity against PBMNCs. Although treatment with 2 µM of As[iii] alone reduced cell viability to 84.8% of the control in PBMNCs, a similar enhanced cytotoxic effect of delphinidin in combination with As[iii] was not observed, indicating that the reduction in cell viability was primarily attributed to As[iii] (Fig. 7B).

As[iii] in NB4 cells treated with As[iii] alone or in combination with delphinidin. Arsenic uptake was measured to examine whether delphinidin affected As[iii] in NB4 cells when combined with As[iii]. After exposure of NB4 cells to 2 µM As[iii] alone or in combination with 8 µM delphinidin for 0, 1, 3 or 6 h, As[iii] was measured by ICP-MS. As shown in Fig. 8, the levels of As[iii] increased with time in NB4 cells following treatment with As[iii] alone. In comparison to treatment with As[iii] alone,
the levels of As[i] decreased slightly, but significantly, in the cells after treatment with As[III] alone and in combination with delphinidin for 1 and 3 h, and were restored at 6 h to the level of the group receiving As[III] alone.

Discussion

In the present study, we have demonstrated that delphinidin exhibited dose- and time-dependent cytotoxic effects on NB4 cells, and exerted more potent cytotoxicity against NB4 cells than normal PBMNCs. Similarly, delphinidin has been demonstrated to inhibit the cell growth of AU-565 and MCF-10A breast cancer cell lines, and to have only minimal effects on normal mammary epithelial 184A1 cells (16). Hafeez et al (15) have demonstrated that delphinidin induces a dose-dependent inhibition of cell growth in LNCaP, C4-2, 22Rv1 and PC3 human prostate cancer cell lines, without having any substantial effects on normal human prostate epithelial cells. Collectively, delphinidin seems to possess a selective cytotoxic activity against tumor cells rather than normal cells.
Cell-cycle arrest is involved in the anti-proliferative effects of a large number of plant-derived agents including delphinidin in various solid tumor cells (17,18). In the case of leukemic cells, it has been demonstrated that quercetin induces cell cycle arrest at G2/M phase in NB4 cells, but not in other leukemic cells such as U937 and HL-60 (12). Moreover, genistein has been demonstrated to provoke a dose- and time-dependent accumulation of cells at G2/M phase in U937 cells (13). These findings suggest that the induction of cell cycle arrest is strongly dependent on the inducer and/or cell types. In the present study, we have demonstrated that almost no cell-cycle arrest, but a time-dependent apoptosis induction, was observed in NB4 cells treated with delphinidin, suggesting that the delphinidin-mediated cytotoxic effect was attributed to apoptosis induction rather than cell cycle arrest. It is well known that the aim of anticancer therapy is generally focused on apoptosis induction in premalignant and malignant cells (32). Our results thus raise a possibility that delphinidin may be developed as an effective chemopreventive and/or chemotherapeutic agent.

To clarify the molecular details of the apoptosis pathway, we focused on the activation of caspases including caspase-3, -8 and -9, which are key players in two principal signaling pathways of apoptosis induction, known as the intrinsic and extrinsic pathways (9,33). The intrinsic mechanism of apoptosis involves a disruption of the mitochondrial cell membrane, resulting in the loss of ΔΨm associated with cytochrome c release, followed by the activation of caspase-3 and -9 (9,32,33). By contrast, the extrinsic pathway induced by death receptors, such as Fas and tumor necrosis factor receptor, is responsible for the activation of caspase-8 accompanied by the activation of caspase-3 (9,32). In the present study, the activation of caspase-8 and -9 was observed as early as 1-h post-exposure to delphinidin, followed by the activation of caspase-3 from 3-h post-exposure, suggesting the contribution of the intrinsic and extrinsic pathways to the delphinidin-triggered apoptosis induction in NB4 cells. We also demonstrated that a substantial decrease in the expression levels of Bid was observed as early as 1-h post-exposure, the same time-point as the activation of caspase-8. Only a modest decrease in ΔΨm was observed at 3-h post-exposure, followed by a substantial time-dependent decrease in ΔΨm in delphinidin-treated NB4 cells. It is noteworthy that the caspase-8-mediated cleavage of Bid into a pro-apoptotic active truncated form provides the connection between the intrinsic and extrinsic pathway (34). It has become clear that truncated Bid translocates to the mitochondria and then leads to a decrease of ΔΨm, following the release of cytochrome c from mitochondria to cytosol (35,36). Taking the previous results and our observations into account, we suggest that truncated Bid, as a result of activation of caspase-8, contributes to the loss of ΔΨm, and further amplifies the apoptotic signal triggered by delphinidin in NB4 cells.

More importantly, we also demonstrated that delphinidin in combination with AsIII achieved an enhanced cytotoxic effect against NB4 cells, but lesser on PBMCs. Although the marked clinical efficacy of AsIII-based regimens against APL has been reported (6,10), its side effects remain a serious concern and limit its clinical applications. The successful application of new AsIII-based therapies may require the generation of sensitizing strategies to improve the efficacy of AsIII, and consequently reduce the drug dose to clinically tolerable concentrations. Flavonoids such as quercetin and genistein have been reported to selectively potentiate AsIII-induced apoptosis via ROS generation resulting from intracellular GSH depletion, and activation of the intrinsic and extrinsic apoptotic pathway in human leukemia cell lines such as HL-60, U937 and THP-1, but not in phytohemagglutinin-stimulated non-tumor peripheral blood lymphocytes (12,13). Collectively, the present results suggest that delphinidin is a promising cancer chemopreventive agent candidate for enhancing the clinical efficacy of AsIII.

Based on an evaluation of the intracellular accumulation of Rhodamine 123 and/or daunorubicin in multidrug-resistant cells expressing P-glycoprotein (Pgp) or non-Pgp multidrug resistance protein, flavonoids such as genistein have been demonstrated to inhibit these drug transporters, resulting in enhanced accumulation of these substrates (37,38). However, in comparison to treatment with AsIII alone, the level of As[i] was decreased by the addition of delphinidin in the first 3 h of treatment, and returned at 6 h to the level of the group receiving AsIII alone. These results suggested that the enhanced cytotoxicity effect of delphinidin in combination with AsIII in NB4 cells may not be attributed to the alterations of As[i]. However, detailed experimental studies focusing on the mechanisms underlying the enhanced cytotoxic effect are needed.

In conclusion, to the best of our knowledge, we have demonstrated for the first time that delphinidin showed selective cytotoxic effects against NB4 cells, but minimal effects on PBMCs. We have also shown that the intrinsic and extrinsic pathways linked by Bid contributed to the cytotoxicity. More importantly, delphinidin selectively sensitized the cells to AsIII, resulting in the enhancement of AsIII cytotoxicity by strengthening intrinsic/extrinsic pathway-mediated apoptosis induction, rather than affecting the levels of As[i]. These observations may offer a rationale for the use of delphinidin to improve the clinical efficacy of AsIII.

Acknowledgements

We thank Professor Steven R. Kayser of UCSF School of Pharmacy for the critical reading of this manuscript. The present study was supported in part by grants from the Japan China Medical Association to Bo Yuan.

References